BioCentury | Jun 28, 2018
Distillery Techniques

Biomarkers

TECHNOLOGY: SNPs SNPs on 124 genomic loci could help predict the risk of myopia and other ocular refractive errors. Genome-wide association studies (GWAS) in 255,925 individuals identified associations between ocular refractive errors including myopia and...
BioCentury | Apr 11, 2017
Distillery Techniques

Drug properties; other

TECHNOLOGY: Pharmacokinetics / pharmacodynamics; drug-drug interactions; computational models A computational model for predicting the PK of ATRA could aid the design of ATRA-dosing strategies and identify drug-drug interactions that could help overcome resistance caused by...
BioCentury | Sep 22, 2016
Distillery Therapeutics

Therapeutics: Aldehyde dehydrogenase 1 family member A1 (ALDH1A1); cytochrome P450 26A1 (CYP26A1; CP26)

Cancer INDICATION: Colorectal cancer Patient sample and mouse studies suggest enhancing all-trans retinoic acid (ATRA) levels could help treat colorectal cancer. In tumor samples from colorectal cancer patients, levels of ALDH1A1 - which participates in the...
BioCentury | Mar 27, 2014
Targets & Mechanisms

Insights into ependymoma

...B tumors. The genes were cysteine-rich protein 1 ( CRIP1 ), cytochrome P450 26C1 ( CYP26C1...
BioCentury | Dec 5, 2005
Clinical News

VTP-201227: Phase II started

Vitae began a double-blind, placebo-controlled, U.S. Phase II trial in 128 patients. Vitae Pharmaceuticals Inc. , Fort Washington, Penn. Product: VTP-201227 Business: Autoimmune Molecular target: NA Description: Topical inhibitor of the enzymes CYP26A and CYP26B Indication:...
BioCentury | Aug 25, 2003
Company News

Cytochroma other research news

Cytochroma said it discovered CYP26C, a member of the cytochrome P450 family. The company said that due to the tissue distribution of CYP26C, inhibitors of the enzyme could be useful in treating CNS disorders. Cytochroma...
Items per page:
1 - 6 of 6